Axsome Therapeutics Inc (AXSM) Ord Shares

Axsome Therapeutics, Inc. is a biopharmaceutical company. The Company is focused on the developing medicines for people impacted by central nervous system (CNS) conditions. Its commercial products include Auvelity, Sunosi and Symbravo. It is also advancing pipeline of novel product candidates in early- to late-stage development addressing a broad range of serious neurological and psychiatric conditions. Its product pipelines include AXS-05, AXS-12, AXS-14 and AXS-17. Its lead product candidate, AXS-05 (dextromethorphan and bupropion), is developed for the treatment of Alzheimer’s disease (AD) agitation and smoking cessation. Its AXS-12 (reboxetine) is a novel, oral, potent, highly selective investigational norepinephrine reuptake inhibitor (NRI) and cortical dopamine modulator being developed for the treatment of narcolepsy. It also owns balipodect, a novel, oral, potent, and selective phosphodiesterase 10A (PDE10A) inhibitor for the treatment of schizophrenia and Tourette syndrome.